Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | MGAM | O43451 | 1/20 | 0.41 |
| ▸ | SI | P14410 | 1/20 | 0.41 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA7 | P43166 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7713280 | 0.83 | GAA (0.55) | CYP1A2CYP2C9CYP2C19ALDH1A1GAA | |
| SCHEMBL101218 | 0.83 | DGAT1 (0.46) | MEN1KMT2AGAACA1CA7 | |
| SCHEMBL3403411 | 0.83 | APLNR (0.49) | CYP1A2CYP2C9CYP2C19HTTALDH1A1 | |
| SCHEMBL1294994 | 0.82 | EGLN1 (0.44) | CYP1A2CYP2C9CYP2C19HTTALDH1A1 | |
| Potassium SCHEMBL29554503 | 0.81 | DGAT1 (0.44) | MEN1KMT2AGAACA1CA7 | |
| SCHEMBL1522412 | 0.81 | DGAT1 (0.44) | MEN1KMT2AGAACA1CA7 | |
| SCHEMBL6272856 | 0.81 | DGAT1 (0.44) | MEN1KMT2AGAACA1CA7 | |
| SCHEMBL28895815 | 0.81 | TDP1 (0.39) | MEN1KMT2AGAACA1CA7 | |
| SCHEMBL15228762 | 0.80 | GAA (0.50) | CYP1A2CYP2C9CYP2C19HTTALDH1A1 | |
| SCHEMBL27907267 | 0.80 | EPHX1 (0.47) | ALDH1A1CA1CA12CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3177601-B1 | TLR-INDEPENDENT SMALL MOLECULE ADJUVANTS | SCRIPPS RESEARCH INST (US) | 2023-03-01 | — | — | EP | disclosed |
| US-20200300843-A1 | Clozapine Immunoassay | SALADAX BIOMEDICAL INC (US) | 2020-09-24 | — | — | US | disclosed |
| EP-2714920-B1 | CLOZAPINE IMMUNOASSAY | SALADAX BIOMEDICAL INC (US) | 2018-05-02 | — | — | EP | disclosed |
| US-9551724-B2 | 5-fluoro-uracil immunoassay | SALADAX BIOMEDICAL, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| EP-1774331-B1 | CYTOXAN ANTIBODIES AND IMMUNOASSAY | SALADAX BIOMEDICAL INC (US) | 2015-09-02 | — | — | EP | disclosed |
| US-20150104818-A1 | GEMCITABINE IMMUNOASSAY | SALADAX BIOMEDICAL INC. | 2015-04-16 | — | — | US | disclosed |
| EP-2544540-B1 | LENALIDOMIDE AND THALIDOMIDE IMMUNOASSAYS | SALADAX BIOMEDICAL INC (US) | 2015-04-08 | — | — | EP | disclosed |
| US-8946392-B2 | Gemcitabine immunoassay | SALADAX BIOMEDICAL INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-20140302618-A1 | Clozapine Immunoassay | SALADAX BIOMEDICAL INC. (US) | 2014-10-09 | — | — | US | disclosed |
| US-20140273023-A1 | GEMCITABINE IMMUNOASSAY | SALADAX BIOMEDICAL INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20010007877-A1 | NOVEL ANTI-INFECTIVES | SMITHKLINE BEECHAM CORPORATION | 2001-07-12 | — | — | US | disclosed |
| WO-2001034146-A1 | NOVEL ANTI-INFECTIVES | SMITHKLINE BEECHAM CORPORATION (US) | 2001-05-17 | — | — | WO | disclosed |
| EP-0399184-B1 | Reagents, methods and kits for an amphetamine-class fluorescence polarization immunoassay | ABBOTT LAB (US) | 1995-09-13 | — | — | EP | disclosed |
| US-5354693-A | Reagents, methods and kits for an amphetamine-class fluorescence polarization immunoassy | ABBOTT LABORATORIES (US) | 1994-10-11 | — | — | US | disclosed |
| US-5248791-A | Reagents, methods and kits for an amphetamine-class fluorescence polarization immunoassay | ABBOTT LABORATORIES (US) | 1993-09-28 | — | — | US | disclosed |
| US-5101015-A | Nitrogen-functional-group-containing immunogen | ABBOTT LABORATORIES (US) | 1992-03-31 | — | — | US | disclosed |
| EP-0399184-A2 | Reagents, methods and kits for an amphetamine-class fluorescence polarization immunoassay | ABBOTT LABORATORIES (US) | 1990-11-28 | — | — | EP | disclosed |
| US-4193917-A | LACTAM COMPOUND USED AS INTERMEDIATE | GLAXO LABORATORIES, LIMITED (GB) | 1980-03-18 | — | — | US | disclosed |
| US-4174318-A | USING A TRIALKYL- OR TRIALKYLAMINOPHOSPHINE AS REDUCING AGENT | GLAXO LABORATORIES LTD. (GB) | 1979-11-13 | — | — | US | disclosed |
| US-4014872-A | ANTIBIOTICS | GLAXO LABORATORIES LIMITED (EN) | 1977-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140273023-A1 | GEMCITABINE IMMUNOASSAY | SAMHD1, GMNN, GEMIN5 | CYP1A2 3742/4885CYP2C9 3162/4885CYP2C19 4014/4885 |
| US-20150104818-A1 | GEMCITABINE IMMUNOASSAY | GMNN, GNG2, GEMIN4 | CYP1A2 4542/4885CYP2C9 4498/4885CYP2C19 4720/4885 |
| US-20200300843-A1 | Clozapine Immunoassay | GAP43, CHAT, PA2G4 | CYP1A2 371/4885CYP2C9 1040/4885CYP2C19 724/4885 |
| US-20140302618-A1 | Clozapine Immunoassay | GAP43, CHAT, PA2G4 | CYP1A2 371/4885CYP2C9 1040/4885CYP2C19 724/4885 |
| US-20010007877-A1 | NOVEL ANTI-INFECTIVES | CTSL, MMP8, SERPINB1 | CYP1A2 4409/4885CYP2C9 4367/4885CYP2C19 4381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.